131 related articles for article (PubMed ID: 29965804)
1. Risk of Venous Thromboembolic Events in Patients With Cancer Treated With Aflibercept: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kanukula R; Ganta S; Sirumalla Y; Salam A; Baddam R; Pasupuleti BC
Am J Ther; 2019; 26(4):e549-e552. PubMed ID: 29965804
[No Abstract] [Full Text] [Related]
2. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
3. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
[TBL] [Abstract][Full Text] [Related]
4. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
Jin K; Shen Y; He K; Xu Z; Li G; Teng L
Clin Transl Oncol; 2010 Aug; 12(8):526-32. PubMed ID: 20709650
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
Wang-Gillam A; Tew WP; Rothenberg ML; Dupont J; Cooper W; Sternas L; Buzenet G; Sosman JA; Spriggs DR; Lockhart AC
Invest New Drugs; 2012 Oct; 30(5):1958-61. PubMed ID: 22002018
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
7. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.
Kitchens JW; Do DV; Boyer DS; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Kaiser PK
Ophthalmology; 2016 Jul; 123(7):1511-20. PubMed ID: 27084563
[TBL] [Abstract][Full Text] [Related]
9. [Inhibition of angiogenesis by proteins, peptides and "small molecules"].
Jayson G; Armand JP; Berdel WE
Onkologie; 2005 Oct; 28 Suppl 4():29-34. PubMed ID: 16205103
[No Abstract] [Full Text] [Related]
10. Cancer-Associated Thrombosis: Regulatory Mechanisms and Emerging Directions.
Prodger A; Saha P; Smith A; Evans CE
Adv Exp Med Biol; 2017; 906():115-122. PubMed ID: 27638621
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
Sonpavde G; Je Y; Schutz F; Galsky MD; Paluri R; Rosenberg JE; Bellmunt J; Choueiri TK
Crit Rev Oncol Hematol; 2013 Jul; 87(1):80-9. PubMed ID: 23317774
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept: osteonecrosis of the jaw: Watch out for high-risk situations.
Prescrire Int; 2016 Nov; 25(176):271. PubMed ID: 30730125
[No Abstract] [Full Text] [Related]
14. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
15. Targeting small molecules in cancer.
Wanebo HJ; Berz D; Mega A
Cancer Treat Res; 2007; 135():239-55. PubMed ID: 17953421
[No Abstract] [Full Text] [Related]
16. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
[No Abstract] [Full Text] [Related]
17. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
Avery RL; Gordon GM
JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept a new target therapy in cancer treatment: a review.
Ricci V; Ronzoni M; Fabozzi T
Crit Rev Oncol Hematol; 2015 Dec; 96(3):569-76. PubMed ID: 26224565
[TBL] [Abstract][Full Text] [Related]
20. Medication-related osteonecrosis of the jaw associated with aflibercept.
Zarringhalam P; Brizman E; Shakib K
Br J Oral Maxillofac Surg; 2017 Apr; 55(3):314-315. PubMed ID: 27923511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
